Intensive polychemotherapy efficacy in young adults with diffuse B-large cells lymphoma from germinal center cells

• Published in: Onkogematologii͡a no. 4; pp. 4 - 11
• Main Authors: M. M. Bobkova, S. V. Semochkin, V. L. Ivanova, O. G. Agafonova, L. A. Antipova, N. N. Volchenko, V. V. Dergacheva, O. D. Zacharov, Yu. A. Kudinov, S. S. Kulikova, Yu. B. Kochkareva, N. A. Lobanova, I. E. Lazarev, E. V. Laricheva, L. A. Magomedova, N. V. Malachova, V. G. Markaryan, L. A. Mucha, S. V. Minenko, T. Yu. Ostrenkova, E. V. Ovanesova, T. N. Perestoronina, M. E. Ribakova, E. A. Samischina, V. V. Ptuschkin
• Format: Journal Article
• Language: Russian
• Published: ABV-press 01-11-2022
• Subjects: adults; diffuse b large-cells lymphoma (dblcl); polychemotherapy
• ISSN: 1818-8346; 2413-4023
• DOI: 10.17650/1818-8346-2009-0-4-4-11

Analysis of treatment results of 165 primary adult patients with diffuse B large-cells lymphoma (DBLCL) treating in Moscow municipal clinics is presented. Study aimed on analysis of efficacy of various dose intensity chemotherapy schedule according to disease molecular genetics variants. 28 adolescents and young adults (median age — 21.7 years) have received treatment according to pediatric BFM-NHL 90m and BFM-NHL 2004M protocols, 46 (median age — 29.0 years) and 91 (median age — 59.5) adults according to courses CHOP and R-CHOP, respectively. It was not randomized study. Germinal and postgerminal variants DBLCL were determined using immunohistochemical technique for 58 (35%) patients with appropriate primary samples. For young patients with germinal DBLCL therapy superiority of intensive BFM-NHL 90m and B-NHL 2004M protocols in relation to postgerminal variants was revealed: 5-years event-free survival (EFS) was 1.0 ± 0.0 (n = 6) versus 0.44 ± 0.15 (n = 9), respectively (p 0.05). Data receiving proves expediency of treatment adolescents and young adults with DBCLC from germinal center cells according to intensity BFM-like protocols.